Tier 2 — strong

Effect of single-dose and short-term administration of quercetin on the pharmacokinetics of talinolol in humans - Implications for the evaluation of transporter-mediated flavonoid-drug interactions

M A Nguyen, P Staubach, S Wolffram, P Langguth
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2014 61:54

Bibliography

PubMed
PMID 24472704
DOI
10.1016/j.ejps.2014.01.003
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignHuman crossover pharmacokinetic interaction study
ModelHuman intervention research
Sample10 healthy volunteers
InterventionSingle-dose and repeated quercetin with the transporter probe talinolol
DurationSingle-dose and short-term comparisons
EndpointsExposure and pharmacokinetics

What the study showed, in plain terms

Published in 2014, this source examined safety, interactions and special populations. Design: Human crossover pharmacokinetic interaction study. Sample/model: 10 healthy volunteers. The exposure or intervention was Single-dose and repeated quercetin with the transporter probe talinolol. Follow-up or treatment period: Single-dose and short-term comparisons.

Average talinolol peak concentration and exposure decreased without statistically significant group differences; some individuals had larger reductions.

Small and variable pharmacokinetic experiment. Dose and schedule require full-method confirmation; clinical treatment outcomes were not tested.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin Interactions: Medicines, Evidence and Precautions. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Average talinolol peak concentration and exposure decreased without statistically significant group differences; some individuals had larger reductions.
  • The recorded outcome domains were Exposure and pharmacokinetics.
  • The result applies to the tested exposure: Single-dose and repeated quercetin with the transporter probe talinolol; Single-dose and short-term comparisons.

What this study can and cannot tell us

  • Small and variable pharmacokinetic experiment. Dose and schedule require full-method confirmation; clinical treatment outcomes were not tested.
  • A change in blood exposure or a metabolic marker is not a demonstrated improvement in symptoms, disease events or lifespan. The tested formulation and co-administered medicines matter.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Phase 1 study of quercetin, a natural antioxidant for children and young adults with Fanconi anemia
Parinda A Mehta et al. · Blood advances · 2025
Tier 2
Randomised clinical trial to determine the safety of quercetin supplementation in patients with chronic obstructive pulmonary disease
Meilan K Han et al. · BMJ open respiratory research · 2020
Tier 2
Interaction study between antiplatelet agents, anticoagulants, diabetic therapy and a novel delivery form of quercetin
Antonella Riva et al. · Minerva cardioangiologica · 2019

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology